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ABSTRACT Inhibitors of the human immunodeficiency
virus type 1 (HIV-1) protease represent a promising addition to
the available agents used to inhibit virus replication in a
therapeutic setting. HIV-1 is capable of generating phenotypic
variants in the face of a variety of selective pressures. The
potential to generate variants with reduced sensitivity to a
protease inhibitor was examined by selecting for virus growth
in cell culture in the presence ofthe protease inhibitor A-77003.
Virus variants grew out in the presence of the inhibitor, and
these variants encoded proteases with reduced sensitivity to the
inhibitor. Variants were identified that encoded changes in
each of the three subsites of the protease that interact with the
inhibitor. HIV-1 displays significant potential for altering its
interaction with this protease inhibitor, suggesting the need for
multiple protease inhibitors with varying specificities.
All retroviruses encode a protease that cleaves the polypro-
tein precursors Gag and Gag/Pol during virus assembly
(reviewed in ref. 1). If protease activity is blocked, then
noninfectious particles are formed, which are composed of
unprocessed precursors (2-4). The viral protease is therefore
an important target for drug development. Numerous com-
pounds that are potent inhibitors of the protease of human
immunodeficiency virus type 1 (HIV-1) and that effectively
inhibit virus replication (5-8) have been developed. The
structure-based design of the C2 symmetric inhibitors has
resulted in a distinct class of antiviral compounds, several of
which exhibit acceptable pharmacologic properties. One
such compound, A-77003 (9), is shown below:
The retroviral protease must interact with a variety of
distinct protein sequences that together constitute the pro-
cessing sites in the Gag and Gag/Pol precursors (reviewed in
ref. 1). Substitutions of the amino acids that make up the
protease subsites, the regions of the protease that interact
with the side chains of the amino acids at the cleavage sites,
can give rise to proteases with altered specificity (10-12).
Thus it appears that the protease has sufficient flexibility in
its sequence requirements to permit sequence variability that
could affect interaction with a protease inhibitor. An initial
demonstration of this possibility was shown by the work of
Otto et al. (13), where selection for HIV-1 replication in the
presence of an inhibitor related to A-77003 resulted in the
outgrowth of a variant with a 6- to 8-fold change in the
sensitivity of the virus to the inhibitor.
Our overall strategy was to use cell culture systems to grow
HIV-1 in the presence of the inhibitor A-77003 and then test
the resulting virus for sensitivity to the inhibitor. In addition,
we have characterized the coding domain of the viral prote-
ase in cultures that had undergone extensive selection. Both
analyses indicate that HIV-1 is capable ofgenerating variants
with reduced sensitivity to the inhibitor, and characterization
of the mutant proteases demonstrates that multiple residues
can be changed to alter the interaction between the protease
and the inhibitor.
METHODS
Selection of Virus Variants. CEM cells were acutely in-
fected (14) with a virus derived from the HXB2 molecular
clone of HIV-1 (15). After 4 hr the cells were placed in a total
volume of 19 ml ofmedium [RPMI 1640 with 2 mM glutamine
and 10% (vol/vol) fetal calf serum]. The medium was re-
placed every 2 days, and the cells were passed at a split ratio
of 1:2 as needed (every 2-3 days). The concentration of
A-77003 used in the initial round of infection was 0.1 LM.
After the infection had spread through the culture (i.e., all of
the cells were involved in syncytia), the cells were pelleted
and the supernatant was used to start the next round of
selection. Cultures were grown in the presence of the previ-
ous concentration of inhibitor and 0.1, 0.2, and 0.3 /AM higher
concentrations of A-77003. The supernatant from the culture
that produced syncytia in the presence of the highest con-
centration of inhibitor was used to initiate the next round of
infection.
In the selection using chronically infected cells, CEM cells
chronically infected with the HIV-1LAI were placed in fresh
medium every 2-3 days, with the inhibitor concentration
maintained at a constant level. When the medium was
replaced, the cells were adjusted to a concentration of 5 x 105
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cells per ml. The chronically infected cell line was established
as the outgrowth of CEM cells acutely infected with HIV-
1LAI. The cells were passaged -40 times prior to selection
with the inhibitor.
A-77003 Sensitivity Testing. Virus titer was determined
using the assay of Kimpton and Emerman (16) or by end-
point dilution using CEM cells. To test for drug sensitivity,
CEM cells were infected with the indicated virus stock by
placing 2 x 106 cells and 2 x 105 infectious units of each virus
in a total of 1.0 ml of tissue culture medium for 5 hr at 370C.
The total volume of medium was then increased to 19 ml.
A-77003 was added to each flask to the indicated concentra-
tion. After 3 days, and each day thereafter, the cells in each
flask were recovered by centrifugation and resuspended in
fresh medium, and the appropriate amount of A-77003 was
added. The sensitivity ofthe different virus stocks to A-77003
was estimated by comparing the concentration of drug
needed to reduce the production of viral p24 capsid antigen
in the cell-free supernatant by 50% (inhibitory concentration
50%, or IC50).
Recovery and Amplification of Protease Coding Domain
Sequences from Infected Cells. Genomic DNA was purified
from -5 x 106 infected cells by lysis [proteinase K (500
pg/ml)/0.5% SDS/10 mM Tris, pH 7.5/30 mM NaCl/20 mM
EDTA, 550C, 2 hr], followed by extraction with phenol/
chloroform and ethanol precipitation. Two rounds of nested-
primer PCR were used to amplify a DNA product containing
the protease coding domain. First round conditions were 2
AM each outer primer, 400 gM of each dNTP, 50 mM KCl,
10 mM Tris (pH 9.0), 1.5 mM MgCl2, 0.1% Triton X-100, 5
units of Taq polymerase (Promega); cycle 1: 94TC for 5 min,
50TC for 60 sec, and 72TC for 90 sec; cycles 2-29: 94TC for 30
sec, 50TC for 60 sec, and 720C for 90 sec; cycle 30: 94TC for
30 sec, 50TC for 60 sec, and 72TC for 10 min. Second round
reactions used the first round product as template and an
interior set of primers but were otherwise identical to first
round conditions. The primer sequences are as follows:
primer 1, 5'-GGAATATTGCTGGTGATCCTTTCCATC-
CC-3'; primer 2, 5'-CTGTTGGAAATGTGGAAAGGAAG-
GACACC-3'; primer 3, 5'-GCACATTGTACTGATAT-
CTAATCCC-3'; primer 4,5'-TTAGGGAAGATCTGGCCT-
TCCTAC-3'.
PCR products were digested with EcoRV and Bgl II and
cloned into pIBI20. Individual clones were isolated in Esch-
erichia coli strain DH5aFIQ and sequenced using a dideoxy
chain-termination protocol for either double-stranded or sin-
gle-stranded templates (United States Biochemical).
Characterization of Mutant Proteases. Mutant protease
coding regions were inserted into a T7-based plasmid (17) and
expressed in E. coli. Protease was purified from the inclusion
body fraction by a modification of the procedure of Cheng et
al. (18) as modified by M. Moody and R.S. (unpublished
results). Protease activity was assayed using a modification
of a radiometric assay described by Ido et al. (19). Reactions
were performed at 300C in 25 A.l with 0.2 M NaCl, 1 mM
dithiothreitol, 0.1% Triton X-100, and 100 mM sodium ace-
tate (pH 5.5). The substrate [3H]Ac-SQNYPIVR had a spe-
cific activity of 11 mCi/mmol (1 Ci = 37 GBq) and was
present at a concentration of 0.5 mM. Reactions were linear
over the 30-min period of incubation with <10% substrate
cleavage and were terminated by the addition of Dowex
X-50W-X4 (5% wt/vol) in 0.1 M acetic acid. The resulting
supernatant contained only the acetylated cleavage product,
which was quantitated by liquid scintillation counting. Ap-
parent Ki values were determined as described (20), using a
nonlinear regression routine (21), which was kindly provided
by D. Northrop (University of Wisconsin).
RESULTS
In Vitro Selection of Less Susceptible Variants in Acutely
Infected Cells. Two approaches were used to select for virus
with reduced sensitivity to the inhibitor. In the first scheme,
virus was passaged in the presence of increasing concentra-
tions ofA-77003. For the initial round of selection, CEM cells
were infected with virus in the presence of 0.1 juM of the
inhibitor (slightly above the IC50). After nine passages in the
presence of an escalating inhibitor concentration, the infec-
tion proceeded in the presence of an inhibitor concentration
of 0.9 JiM.
Virus harvested at the end of passages 4 and 8 was assayed
for sensitivity to A-77003. Virus passaged nine times without
inhibitor remained sensitive to the inhibitor (Fig. 1A). A
change in sensitivity was observed, however, with the virus
passaged in the presence of inhibitor (Fig. 1B). We estimate
there is an =10-fold increase in the IC"0 ofthe virus produced
by passage in the presence of inhibitor. Virus obtained after
four passages in the presence of inhibitor was indistinguish-
able in its sensitivity compared to the parental virus (data not
shown).
We examined the protease sequence for the presence of
mutations using the PCR to amplify the complete protease
coding domain. The amplified viral DNA was cloned in a
phagemid vector, and individual clones were sequenced until
the extent of sequence heterogeneity within the population
could be assessed. A comparison of the sequences from the
parent virus with those obtained from the passage 6 virus
demonstrates that several changes accumulated during the
selection period (Fig. 2A). Encoded amino acid changes that
appeared more than twice in 40 clones are valine at position
32 replaced by isoleucine (V321), valine at position 82 re-
placed by isoleucine (V821), and methionine at position 46




FIG. 1. HIV-1 passaged in the presence of the symmetric prote-
ase inhibitor A-77003 displays reduced sensitivity. Sensitivity testing
was performed on virus stocks generated by passage in the absence
(A) or presence (B) of increasing concentrations of A-77003. Virus
growth was monitored in the absence of inhibitor (0) or in the
presence of0.1 ,uM (e), 1.0 pM (m), or 1.5 ,M (o) A-77003. The virus
stocks used for these experiments were generated by the transfection
ofHeLa cells with the HXB2 infectious clone (15) using the calcium
phosphate method (22).
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FIG. 2. Deduced amino acid sequences of HIV-1 protease domains amplified from HIV-1-infected cells cultured in the presence of A-77003.
Virus was grown either by passage of culture supernatants into fresh cultures with increasing concentrations of inhibitor (acute infection) or
by passage of infected cells at constant inhibitor concentration (chronic infection). (A) Sequences derived from the sixth passage of an acutely
infected culture. The A-77003 concentration in the culture was 0.4 ,uM at this point. (B) Sequences derived from the ninth passage of an acutely
infected culture. The A-77003 concentration in the culture was 0.9 pM at this point. (C) Sequences derived from chronically infected cells after
3 months of culture in the presence of 1.0 uM A-77003. (D) Sequences derived from chronically infected cells after 3 months of culture in the
presence of 10 pM A-77003.
more distinctive by passage 9. At this point, 10 of 16 clones
had the valine to isoleucine change at position 32, and 6 of 16
clones had the valine to isoleucine change at position 82.
Furthermore, 3 of these 16 clones were substituted at both
positions 32 and 82 to encode isoleucine (V32I/V821) (Fig.
2B). Two of the 16 clones had leucine substituted for methi-
onine at position 46. An examination of the viral sequences
derived from virus passaged in the absence of selection
revealed six unrelated substitutions in 23 clones sequenced
(data not shown).
In Vitro Selection of Less Susceptible Variants in Chronically
Infected Cells. The second selection scheme took advantage
of the continued replication of HIV-1 in cells chronically
infected with the virus (23). The chronically infected cells
were grown in the presence of either 1.0 ,uM or 10 pM of
A-77003 for 3 months. In the presence of 10 ,uM of A-77003,
supernatantp24 antigen declined by -100-fold within the first
2 weeks of culture and remained relatively constant. Only
modest declines were observed in the presence of the inhib-
itor at 1 p.M. Supernatant infectivity in the presence of either
1 juM or 10 p.M A-77003 declined to zero after only 1 week.
However, at the end ofthe 3-month period, infectivity, albeit
low, was again observed in the supernatant of these cultures,
suggesting that selection had given rise to a less sensitive
virus population (data not shown).
We amplified proviral DNA from the chronically infected
cells selected for 3 months at the two drug concentrations. Of
the clones isolated from the culture selected with 1.0 pM
Table 1. Apparent Ki values for A-77003
Apparent
Protease Ki, nM
WT 0.5 ± 0.1
V82I 0.5 ± 0.1
M46L 1.3 ± 0.2
M46F 2.0 ± 0.5
V321 3.8 ± 0.7
V32I/V821 11 ± 1
R8Q 31 ± 9
WT, wild type. In the designation of mutations, the wild-type
amino acid precedes the HIV-1 protease residue number, followed by
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FIG. 3. Modeling of altered interactions between A-77003 and
mutant HIV-1 proteases. (Top) The structure of A-77003 and its van
der Waals surface are shown with the positions of selected side chains
ofthe wild-type HIV-1 protease (24). The side chains shown are Arg8,
Val32, and Val82; equivalent side chains from the second subunit of
the protease dimer are also shown (Arg108, Val132, and Val182).
(Middle) The van der Waals surface of the inhibitor isopropyl side
chain occupying the P2 position is shown (white) with the van der
Waals surface of the wild-type VaI32 side chain (red) and the substi-
tuted 11e32 side chain and its van der Waals surface (blue). (Bottom)
The structure and van der Waals surface of the inhibitor'P1 benzyl
group and P3 pyridyl group are shown (white). Also shown are the van
der Waals surface of the wild-type Val82 side chain of the protease
(red) as well as the mutant Ile82 side chain and its van der Waals
surface (blue). Modeling was done by addition of a methylene group
A-77003, 18 of 19 encoded phenylalanine instead of methio-
nine at position 46 (M46F; Fig. 2C). Of the clones isolated
from the culture selected with 10 ,AM A-77003, all 13 encoded
glutamine instead of arginine at position 8 (R8Q; Fig. 2D).
Sequences obtained from 12 clones recovered from chroni-
cally infected cells passaged in the absence of inhibitor
showed minor variations unrelated to the changes seen after
selection (data not shown).
Susceptibility of the Mutant Enzymes to A-77003. Viral
protease coding domains coding the substitutions R8Q, V32I,
V32I/V82I, M46L, M46F, and V82I were expressed in E.
coli. The protease variants were purified and individually
tested for sensitivity to A-77003 (Table 1). The apparent Ki for
the V821 mutant was no different from that obtained using
wild-type protease. However, the V321 mutant and the R8Q
mutant were -7- and 60-fold less sensitive to inhibition by
A-77003, respectively. The double mutant V32I/V821 had an
apparent K, that was =20-fold greater than wild-type prote-
ase. A leucine or phenylalanine mutation at position 46
yielded an enzyme that was =2- to 4-fold less sensitive to
A-77003 inhibition compared to the wild-type protease.
Evaluation of the Structural Basis for the Reduced Drug
Sensitivity. The structural basis for the reduced drug sensi-
tivity of the various protease mutants was evaluated with
reference to the crystal structure of the A-77003/HIV-1
protease complex (24). The wild-type residues V82, V32, and
R8 make symmetry-related side chain contacts with the
inhibitor in the S1/S1', S2/S2', and S3/S3' subsites, respec-
tively (Fig. 3 Top). M46 is on the protease flap, and its side
chain extends into the solvent.
We modeled the V321 and V821 mutations into the crystal
structure of the A-77003/HIV-1 protease complex (Fig. 3
Middle and Bottom). Both substitutions lead to repulsive van
der Waals interactions due to steric overlap. In the case of
V321, the isoleucine residue is tightly packed and has little
room for adjustment. The inhibitor may still bind, but with
lower affinity, presumably due to a repositioning of the
isopropyl P2 and P2' side chains of the inhibitor. In the V82I
mutant, the isoleucine side chain has more freedom of
movement within the S1/S1' subsites to help alleviate repul-
sive contacts with the P1/P1' benzyl groups of A-77003. The
synergistic effects of V82I and V32I may be explained by the
fact that these two bulky substituents closely impinge on
opposite sides of the inhibitor in a pincer-like fashion (Fig. 3
Top).
The protease variant with the largest increase in the
apparent Ki, R8Q, was shown to result in decreased van der
Waals and charge-induced dipole interactions between the
enzyme guanidinium and inhibitor pyridine groups (25). The
selection of mutations at M46 is more difficult to rationalize
on structural grounds since this residue does not play a direct
role in binding to A-77003.
DISCUSSION
Inhibitors of the protease of HIV-1 have significant potential
as therapeutic agents in the treatment of AIDS. One concern
in the use of any drug is the possibility that resistant virus
variants might arise during therapy, as has been seen with
inhibitors to the HIV-1 reverse transcriptase (26). We have
evaluated the growth of HIV-1 in the presence of a small
molecule protease inhibitor and determined that virus pop-
ulations with reduced sensitivity may develop during selec-
tion in cell culture. An analysis of the evolution of protease
to valine and adjustment to give a conformation typical of isoleucine.
It was possible to rotate the V821 modeled structure to minimize close
contacts, while the V32I modeled structure had unfavorabl contacts
in all orientations examined. No minimiation was done to adjust the
positions of other side chains in the modeled structures.
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coding domain sequences indicates that specific substitu-
tions, which represent minority subpopulations early in se-
lection, ultimately predominate in the culture. The amino
acid substitutions are predicted to result in unfavorable
interactions between the inhibitor and the enzyme.
HIV-1 with the protease substitution R8Q is attenuated for
growth (ref. 25; unpublished observation). Thus, the appear-
ance of this mutation, which was also selected by Ho et al.
(25) using A-77003, demonstrates the strong antiviral effect of
A-77003, which can lead to the selection of a variant with
reduced replicative capacity. A virus with the protease
double substitution V32I/V82I grows well as a virus and has
a 5- to 10-fold increase in its IC50 (unpublished observation).
Otto et al. (13) have recently shown that selection with a
related C2 symmetric inhibitor resulted in the appearance of
an HIV-1 variant with a V82A substitution and that this
variant had a 6- to 8-fold reduction in sensitivity to this
compound. One example of this substitution was seen in our
selection of chronically infected cells at 1 pM inhibitor
concentration (Fig. 2C); in this case, the V82A substitution
occurred with the M46F substitution in the flap. A substitu-
tion at position 84 (184V) has also been detected after
selection with another protease inhibitor (27).
Our analysis of the virus variants encoding proteases with
reduced sensitivity to A-77003 indicates that all three subsites
at which this inhibitor contacts the protease can be mutated.
This suggests that the virus has significant flexibility to alter
the interaction between the protease and the inhibitor and
still maintain the functional properties of the protease re-
quired for virus replication. Knowledge of the changes that
alter the sensitivity ofHIV-1 to A-77003 provides a data base
with which to evaluate sequence heterogeneity in patients
undergoing therapy with this type of inhibitor. In addition,
the mutant proteases represent important reagents for testing
other classes of protease inhibitors for cross-resistance.
Finally, an understanding of the mechanism of altered sen-
sitivity provides an opportunity for the design and testing of
new inhibitors that can take advantage of the sequence
variants likely to arise after initial treatment.
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